Over the last 12 months, Enliven Therapeutics insiders reported no purchases and 9 sales totaling $63.2M across SEC Form 4 filings. 78% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Derynck Mika KD | ▼ Sale | 158,795 | $60.21 | $9.6M | -100% | plan |
| Jul 17, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 6,018 | $52.64 | $317K | -11.6% | plan · 5 tranches |
| Jul 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $52.67 | $263K | -16.7% | plan · 5 tranches |
| Jul 6, 2026 | Kunkel Lori AnneD | ▼ Sale | 10,000 | $50.49 | $505K | -19.3% | plan · 2 tranches |
| Jun 22, 2026 | ORBIMED ADVISORS LLC10% | ▼ Sale | 860,123 | $45.36 | $39.0M | -11.6% | 4 tranches · indirect |
| Jun 17, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 6,018 | $43.8 | $264K | -10.6% | plan · 3 tranches |
| Jun 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $43.8 | $219K | -16.7% | plan · 3 tranches |
| Jun 15, 2026 | ORBIMED ADVISORS LLC10% | ▼ Sale | 281,408 | $45.02 | $12.7M | -3.7% | 2 tranches · indirect |
| Jun 5, 2026 | Kunkel Lori AnneD | ▼ Sale | 10,000 | $34.54 | $345K | -16.2% | plan · 3 tranches |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ELVN feed.